Japan's Kissei Pharmaceutical, the local distributor of Amgen's rare‑disease therapy Tavneos, alerted physicians that twenty patients have died after receiving the drug. At least twenty‑two additional cases involved severe liver damage that could prove fatal. Kissei issued an urgent directive on Friday urging doctors to halt new prescriptions while the safety signal is investigated.

The warning follows a broader FDA notice that connected Tavneos to hepatic injury, prompting regulators worldwide to scrutinise the drug's risk profile. Tavneos, approved for anti‑neutrophil cytoplasmic antibody‑associated vasculitis, accounts for a modest share of Amgen's specialty‑drug revenue, but the Japanese market represents a growth foothold for the biotech giant. A sudden drop in sales could pressure Amgen's quarterly earnings and spur a reassessment of its rare‑disease pipeline.

Investors are likely to watch Amgen's response closely, as the company must balance ongoing clinical development with potential liability exposure. A recall or market withdrawal in Japan could set a precedent for other jurisdictions, amplifying legal and reputational risks. Amgen has not publicly commented on the Kissei alert, leaving market participants to gauge the fallout based on regulatory filings.

Analysts predict that the incident may tighten prescribing habits and prompt insurers to revisit coverage terms for Tavneos. Short‑term revenue impact may be limited, but the episode underscores the vulnerability of niche therapeutics to safety scares, reinforcing the need for robust pharmacovigilance across all markets.